AxoGen Inc
F:LT3
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
AxoGen Inc
F:LT3
|
US |
|
S
|
Southwest Airlines Co
XMUN:SWN
|
US |
|
M
|
Marubeni Corp
DUS:MARA
|
JP |
|
People's Insurance Company Group of China Ltd
OTC:PINXF
|
CN |
|
Airbus SE
PAR:AIR
|
NL |
AxoGen Inc
AxoGen makes medical products used to repair and protect damaged peripheral nerves, the nerves outside the brain and spinal cord. Its main products are used by surgeons in procedures for traumatic injuries and other nerve damage, especially when a cut or loss of nerve tissue needs a bridge or protective wrap to help the nerve heal. The company’s business is built around selling these implantable nerve repair products to hospitals, surgical centers, and doctors who perform reconstructive and trauma surgery. Its best-known products include processed nerve tissue grafts and nerve protection devices that help connect or shield injured nerves during surgery. AxoGen makes money by selling these single-use implants through medical distributors and direct sales relationships with healthcare providers. Because these products are used inside the operating room, the company depends on surgeon adoption, hospital purchasing decisions, and reimbursement from the healthcare system. What makes AxoGen different is its narrow focus on peripheral nerve repair, a small but specialized corner of the medical device industry. Instead of selling broad hospital equipment, it concentrates on tools that help surgeons restore nerve function after injury, which puts it at the intersection of regenerative medicine, trauma care, and surgical reconstruction.
AxoGen makes medical products used to repair and protect damaged peripheral nerves, the nerves outside the brain and spinal cord. Its main products are used by surgeons in procedures for traumatic injuries and other nerve damage, especially when a cut or loss of nerve tissue needs a bridge or protective wrap to help the nerve heal. The company’s business is built around selling these implantable nerve repair products to hospitals, surgical centers, and doctors who perform reconstructive and trauma surgery.
Its best-known products include processed nerve tissue grafts and nerve protection devices that help connect or shield injured nerves during surgery. AxoGen makes money by selling these single-use implants through medical distributors and direct sales relationships with healthcare providers. Because these products are used inside the operating room, the company depends on surgeon adoption, hospital purchasing decisions, and reimbursement from the healthcare system.
What makes AxoGen different is its narrow focus on peripheral nerve repair, a small but specialized corner of the medical device industry. Instead of selling broad hospital equipment, it concentrates on tools that help surgeons restore nerve function after injury, which puts it at the intersection of regenerative medicine, trauma care, and surgical reconstruction.
Revenue: Axogen posted first-quarter revenue of $61.5 million, up 26.6% year over year, with growth described as broad-based across all three target markets.
Guidance: Management raised full-year 2026 guidance to at least 20% revenue growth, or at least $270 million of revenue, while keeping gross margin guidance at 74% to 76% and expecting to stay free cash flow positive.
Coverage: The company highlighted new payer progress, including Cigna extending broad coverage and Elevance removing Avance from its experimental list, though management said these changes will take time to show up in results.
Biologic launch: Axogen has begun selling BLA-produced Avance, with the main financial impact expected at gross margin as higher biologic manufacturing costs flow through in the second quarter.
Execution: Commercial hiring, surgeon activation, and education programs were all said to be progressing ahead of plan or on plan, supporting management’s confidence in longer-term growth.
